<DOC>
	<DOCNO>NCT01345968</DOCNO>
	<brief_summary>The primary purpose study evaluate safety efficacy preoperative intravenous ferric carboxymaltose patient anemia undergo hip knee replacement</brief_summary>
	<brief_title>Intravenous Ferric Carboxymaltose ( Ferinject ) Patients Undergoing Orthopaedic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>age &gt; = 18 year Patients schedule undergo hip knee replacement 8 g/dl &lt; Hb &lt; 13 g/dl men 8 g/dl &lt; Hb &lt; 12 g/dl woman screen ( 34 week prior surgery ) anemia sign write informed consent immunosuppressive myelosuppressive therapy history thromboembolic event concurrent medical condition ( ) would prevent compliance participation jeopardize health patient hypersensitivity component formulation transfusion within 1 month prior study inclusion liver value 3 time higher normal active severe infection/inflammation renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>transfusion</keyword>
	<keyword>intravenous ferric carboxymaltose</keyword>
</DOC>